Adolescent, young adult cancer non-profits provide guidance on COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Six non-profit adolescent and young adult cancer advocacy organizations have launched CovidAYACancer.org, a resource for young people with cancer and the health professionals who treat them.

Teen Cancer America, Stupid Cancer, The Leukemia and Lymphoma Society, Cancer and Careers, Lacuna Loft and CureSearch have formed an alliance with oncology specialists, including Craig Nichols, Archie Bleyer and Stu Seigel, to develop the website.

CovidAYACancer.org aims to be a repository for critical information specifically benefittng AYA cancer patients, patient advocates and medical professionals working with this unique population.

Oncologists in the AYA cancer field treat immunocompromised patients who are at elevated levels of risk as a result of COVID-19.

CovidAYACancer.org provides AYA cancer patients and survivors with financial resources, virtual events, employment and psychosocial support. It plans to provide access to online supportive programs and guidance to patients and their families.

The site also provides guidelines for doctors and frontline health teams. Nichols, Bleyer and Siegel have been consulting with colleagues about best practices during COVID-19, as normal protocols for oncological treatment have changed significantly.

The CovidAYACancer alliance is supported by international pharmaceutical company Servier, which is providing coordination and technical support.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login